Giulia Benevolo: Influence Statistics

Giulia Benevolo

Giulia Benevolo

Division of Haematology, Città della Salute e della Scienza Hospital, Turin, Italy | SC Ematologia, AOU Città della Salute e della Scienza di Torino-Presidio Ospedaliero ...

Giulia Benevolo: Expert Impact

Concepts for which Giulia Benevolo has direct influence: Polycythaemia vera , Multiple myeloma , Pooled analysis , Patients myelofibrosis , Arterial thrombosis , Myeloma patients , Complete response .

Giulia Benevolo: KOL impact

Concepts related to the work of other authors for which for which Giulia Benevolo has influence: Multiple myeloma , Polycythemia vera , Myeloproliferative neoplasms , Essential thrombocythemia , Elderly patients , Maintenance therapy , Primary myelofibrosis .

KOL Resume for Giulia Benevolo

Year
2022

Division of Haematology, Città della Salute e della Scienza Hospital, Turin, Italy

2021

SC Ematologia, AOU Città della Salute e della Scienza di Torino-Presidio Ospedaliero Molinette, Turin, Italy.

Hematology, AOU Città della Salute e della Scienza di Torino, Turin, Italy

2020

Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy;

2019

SC Hematology AO Città della Salute e della Scienza, Turin, Italy

2018

SC Hematology, Città della Salute e della Scienza Hospital, Torino, Italy

2017

Division of Hematology, Città della Salute e della Scienza Hospital, Torino, Italy.

2016

Struttura Complessa (SC) Ematologia, Dipartimento di Ematologia ed Oncologia, AOU Città della Salute e della Scienza di Torino, San Giovanni Battista, Torino, Italy;

2015

Antonio Palumbo, Francesca Gay, Federica Cavallo, Alessandra Larocca, Francesca Donato, Chiara Cerrato, Luana Boccadifuoco, and Mario Boccadoro, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Giulia Benevolo, S.C. Ematologia A.O. Città della Salute e della Scienza di Torino; Tommasina Guglielmelli, University of Turin and San Luigi Hospital; Giovannino Ciccone, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and CPO Piemonte, Torino; Francesco Di Raimondo, Ospedale Ferrarotto, Azienda Policlinico-OVE, University of Catania, Catania; Maria T. Petrucci, Sapienza University of Rome; Tommaso Caravita, Ematologia Ospedale S. Eugenio, Rome; Sara Pezzatti, Azienda Ospedaliera San Gerardo, Monza; Francesca Patriarca, DISM, University Hospital, Udine; Chiara Nozzoli, AOU Careggi, Florence; Donatella Vincelli, A.O "Bianchi-Melacrino-Morelli," Reggio Calabria; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Referral Cancer Center of Basilicata, Rionero in Vulture; Paolo Corradini, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano; Michele Cavo, Institute of Hematology and Medical Oncology "Seràgnoli," Bologna University School of Medicine S. Orsola's University Hospital, Bologna, Italy; Izhar Hardan, Meir Medical Center, Kfar-Saba; Arnon Nagler, Tel Aviv University, Chaim Sheba Medical Center, Tel-Hashomer, Israel; Roman Hajek, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic; Michel Delforge, University Hospital Leuven, Leuven, Belgium; Zhinuan Yu and Christian Jacques, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece.

2013

GIMEMA, Italian Multiple Myeloma Network, Rome, Italy,

2012

GIMEMA Multiple Myeloma Working Party and Italian Myeloma Network, Rome, Italy,

2011

Multiple Myeloma Working Party and Italian Myeloma Network, GIMEMA, Rome, Italy,

Prominent publications by Giulia Benevolo

KOL-Index: 8497 . PURPOSE: Continuous therapy (CT) prolongs progression-free survival 1 (PFS1; time from random assignment until the first progression or death), but chemotherapy-resistant relapse may negatively impact overall survival (OS). Progression-free survival 2 (PFS2; time from random assignment until the second progression or death) may represent an additional tool to estimate outcome. This study ...
Known for Continuous Therapy | Pfs1 Pfs2 | Fixed Duration | Diagnosed Multiple
KOL-Index: 8252 . BACKGROUND: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the ...
Known for Patients Myelofibrosis | Discontinuation Ruxolitinib | Blast Phase | Loss Response
KOL-Index: 6986 . We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of ...
Known for Patients Cancer | Myeloproliferative Neoplasms | Mpn Diagnosis | Philadelphia Negative
KOL-Index: 6900 . BACKGROUND: There is no evidence that phlebotomy alone is sufficient to steadily maintain haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to compare the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with phlebotomy alone. METHODS: In 2017, we launched the Low-PV study, a multicentre, open-label, two-arm, ...
Known for Polycythaemia Vera | 50 Patients | Janus Kinase | Ropeginterferon Alfa2b
KOL-Index: 6498 . Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus low-dose dexamethasone (Rd). The primary end point was ...
Known for Elderly Patients | Multiple Myeloma | Median Pfs | Primary Point
KOL-Index: 5285 . In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By ...
Known for Spleen Response | 6 Months | Patients Myelofibrosis | Ruxolitinib Rux
KOL-Index: 5141 . Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. ...
Known for Arterial Thrombosis | Myeloproliferative Neoplasms | Thrombotic Events | Mpn Patients
KOL-Index: 5105 . Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment for newly diagnosed MM, particularly in patients with high-risk cytogenetics [del(17p), ...
Known for Pooled Analysis | Multiple Myeloma | Standardrisk Patients | Bortezomib Dexamethasone
KOL-Index: 4121 . BackgroundSeveral new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatment blood and bone marrow plasma concentrations of major cytokines and angiogenic factors (CAFs) of patients from a phase 3 trial of a MM treatment could have a prognostic ...
Known for Multiple Myeloma | Bone Marrow | Mm Patients | Prognostic Predictive
KOL-Index: 3212 . PurposeMaintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and ...
Known for Maintenance Patients | Induction Consolidation | Multiple Myeloma | Complete Response
KOL-Index: 2899 . PurposeMyelofibrosis (MF) is a chronic myeloproliferative neoplasm characterised by an aggressive clinical course, with disabling symptoms and reduced survival. Patients experience a severely impaired quality of life and their families face the upheaval of daily routines and high disease-related financial costs. The aim of this study was to investigate the perceptions of Italian patients ...
Known for Narrative Medicine | Patients Caregivers | Cost Illness | Italy Male
KOL-Index: 2564
Known for Polycythemia Vera | Essential Thrombocythemia | Mysec Project | Primary Myelofibrosis
KOL-Index: 1508
Known for Myeloproliferative Neoplasms | Direct Oral Anticoagulants | Atrial Fibrillation | Venous Thromboembolism

Key People For Polycythaemia Vera

Top KOLs in the world
#1
Tefferi Tefferi
essential thrombocythemia primary myelofibrosis polycythemia vera
#2
Tiziano Barbui
polycythemia vera essential thrombocythemia myeloproliferative neoplasms
#3
Guido Finazzi
polycythemia vera essential thrombocythemia myeloproliferative neoplasms
#4
LOUIS ROBERT WASSERMAN
polycythemia vera intrinsic factor pernicious anemia
#5
Heinz Gisslinger
polycythemia vera multiple myeloma essential thrombocythemia
#6
Claire N Harrison
speakers bureau board directors advisory committees

Division of Haematology, Città della Salute e della Scienza Hospital, Turin, Italy | SC Ematologia, AOU Città della Salute e della Scienza di Torino-Presidio Ospedaliero Molinette, Turin, Italy. | Hematology, AOU Città della Salute e della Scienza di